What is Lifecore Biomedical Inc's earnings per share (EPS)?

Lifecore Biomedical Inc (LFCR) reported diluted earnings per share of -$1.27 for fiscal year 2025. This represents a -484.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Lifecore Biomedical Inc Financials

LFCR

FY2025 annual

Revenue $128.9M +0.5% YoY

Net Income -$38.7M -422.5% YoY

EPS (Diluted) -$1.27 -484.8% YoY

Free Cash Flow -$13.6M +24.9% YoY

Source SEC Filings (10-K/10-Q) Latest period Q1 FY2027, ended Jun 30, 2026 Reported Aug 5, 2026 Currency USD FYE May

Lifecore Biomedical Inc (LFCR) reported $128.9M in revenue for fiscal year 2025, up 0.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI LFCR FY2025 2026-08-15

Revenue plateau and a heavier financing burden keep the company operating below break-even.

Earnings-to-cash conversion was weak in FY2024: $12M of net income produced only $257K of operating cash flow, while free cash flow remained negative. In FY2025, the return to a net loss alongside negative operating cash flow made the accounting result more consistent with the company’s cash-consuming operations.

Revenue was essentially flat between FY2024 and FY2025, yet operating margin worsened to -13.4%; stable scale is not translating into operating profit. Gross margin improved from 27.1% in FY2023 to 31.3% in FY2025, so the main drag sits below gross profit, particularly selling, general and administrative expense.

Debt rose from $100.8M in FY2024 to $130.4M in FY2025 while equity turned negative, shifting the balance sheet toward creditor financing. Although the current ratio was 2.8x, cash was only $8.3M, so near-term liquidity depends on converting inventory and other current assets rather than simply holding cash.

Financial Health Signals

Financial Health Score 52/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Lifecore Biomedical Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Dilution

R&D Intensity

Revenue Progress

Burn Trend

Balance Sheet

Altman Z-Score Distress

-0.19

Lifecore Biomedical Inc scores -0.19, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($171.9M) relative to total liabilities ($240.2M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Weak

3/9

Lifecore Biomedical Inc passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Lifecore Biomedical Inc reported a net loss of $38.7M while operations used $206K of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Lifecore Biomedical Inc reported an operating loss of $17.2M against $22.2M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$128.9M

YoY+0.5%

5Y CAGR-4.2%

10Y CAGR-13.3%

Lifecore Biomedical Inc generated $128.9M in revenue in fiscal year 2025. This represents an increase of 0.5% from the prior year.

EBITDA

-$9.2M

YoY-935.7%

Lifecore Biomedical Inc's EBITDA was -$9.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 935.7% from the prior year.

Net Income

-$38.7M

YoY-422.5%

Lifecore Biomedical Inc reported -$38.7M in net income in fiscal year 2025. This represents a decrease of 422.5% from the prior year.

EPS (Diluted)

-$1.27

YoY-484.8%

Lifecore Biomedical Inc earned -$1.27 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 484.8% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$13.6M

YoY+24.9%

Lifecore Biomedical Inc recorded an outflow of $13.6M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents an increase of 24.9% from the prior year.

Cash & Debt

$8.3M

YoY-2.3%

5Y CAGR+87.1%

10Y CAGR-5.2%

Lifecore Biomedical Inc held $8.3M in cash against $130.4M in long-term debt as of fiscal year 2025.

Shares Outstanding

37M

YoY+21.2%

Lifecore Biomedical Inc had 37M shares outstanding in fiscal year 2025. This represents an increase of 21.2% from the prior year.

Dividends Per Share

Not reported for fiscal year 2025.

Margins & Returns

Gross Margin

31.3%

YoY-1.4pp

5Y CAGR+6.7pp

10Y CAGR+19.1pp

Lifecore Biomedical Inc's gross margin was 31.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 1.4 percentage points from the prior year.

Operating Margin

-13.4%

YoY-6.5pp

5Y CAGR+2.8pp

10Y CAGR-16.8pp

Lifecore Biomedical Inc's operating margin was -13.4% in fiscal year 2025, reflecting core business profitability. This is down 6.5 percentage points from the prior year.

Net Margin

-30.0%

YoY-39.4pp

5Y CAGR-6.2pp

10Y CAGR-32.5pp

Lifecore Biomedical Inc's net profit margin was -30.0% in fiscal year 2025, showing the share of revenue converted to profit. This is down 39.4 percentage points from the prior year.

Return on Equity

Not reported for fiscal year 2025.

Capital Allocation

R&D Spending

$8.3M

YoY-3.7%

5Y CAGR+1.7%

10Y CAGR+1.7%

Lifecore Biomedical Inc invested $8.3M in research and development in fiscal year 2025. This represents a decrease of 3.7% from the prior year.

Capital Expenditures

$13.4M

YoY-27.1%

Lifecore Biomedical Inc invested $13.4M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 27.1% from the prior year.

Share Buybacks

Not reported for fiscal year 2025.

LFCR Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

LFCR quarterly income statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Revenue	$128.9M+0.5%	$128.3M+24.2%	$103.3M-7.2%	$111.3M+10.3%	$100.9M-37.0%	$160.1M-71.3%	$557.6M+6.4%	$524.2M+11.6%	$469.8M-1.5%	$476.9M-11.6%	$539.3M+13.1%	$476.8M+7.9%	$441.7M+39.1%	$317.6M+14.8%	$276.7M
Cost of Revenue	$88.6M+2.5%	$86.4M+14.8%	$75.3M+4.3%	$72.2M+16.6%	$61.9M-48.7%	$120.7M-74.7%	$476.6M+6.9%	$445.9M+14.2%	$390.6M-4.8%	$410.1M-13.4%	$473.9M+14.4%	$414.2M+9.3%	$378.9M+42.8%	$265.4M+15.4%	$230.0M
Gross Profit	$40.3M-3.7%	$41.9M+49.5%	$28.0M-28.4%	$39.1M+0.3%	$38.9M-1.1%	$39.4M-51.4%	$81.0M+3.4%	$78.3M-1.1%	$79.2M+18.6%	$66.8M+2.1%	$65.4M+4.5%	$62.6M-0.3%	$62.8M+20.4%	$52.1M+11.7%	$46.7M
R&D Expenses	$8.3M-3.7%	$8.6M-1.8%	$8.7M+11.4%	$7.8M+17.3%	$6.7M-11.8%	$7.6M-33.9%	$11.5M-10.4%	$12.8M+35.1%	$9.5M+31.1%	$7.2M+3.4%	$7.0M-3.0%	$7.2M-22.5%	$9.3M-3.4%	$9.6M+3.8%	$9.3M
SG&A Expenses	$44.0M+8.9%	$40.5M+3.8%	$39.0M+12.4%	$34.7M+25.0%	$27.7M-31.8%	$40.7M-34.5%	$62.1M+19.5%	$52.0M-1.0%	$52.5M+13.7%	$46.2M+15.6%	$40.0M+13.6%	$35.2M+8.1%	$32.5M+22.7%	$26.5M+7.7%	$24.6M
Operating Income	-$17.2M-95.0%	-$8.8M+59.4%	-$21.8M-84.9%	-$11.8M-33.6%	-$8.8M+65.9%	-$25.9M-572.6%	$5.5M-59.7%	$13.6M-7.4%	$14.7M+171.1%	-$20.6M-211.7%	$18.5M-8.6%	$20.2M-18.8%	$24.9M+70.6%	$14.6M+81.5%	$8.0M
Interest Expense	$22.2M+22.2%	$18.1M+2.8%	$17.6M+13.5%	$15.6M+74.1%	$8.9M+92.3%	$4.6M	N/A	N/A	N/A	$2.0M+8.6%	$1.8M+10.8%	$1.6M-17.8%	$2.0M+116.1%	$929K+13.3%	$820K
Income Tax	$43K-76.5%	$183K-40.6%	$308K+105.9%	-$5.2M+17.9%	-$6.3M+27.6%	-$8.8M-678.0%	$1.5M+116.2%	-$9.4M-331.8%	$4.0M+152.4%	-$7.7M-199.5%	$7.7M-26.8%	$10.6M+12.0%	$9.5M+31.6%	$7.2M+71.8%	$4.2M
Net Income	-$38.7M-422.5%	$12.0M+112.0%	-$99.6M+14.7%	-$116.7M-261.4%	-$32.3M+15.4%	-$38.2M-9392.2%	$411K-98.3%	$24.8M+134.5%	$10.6M+191.0%	-$11.6M-185.9%	$13.5M-29.3%	$19.1M-15.2%	$22.6M+77.9%	$12.7M+223.9%	$3.9M
EPS (Diluted)	-$1.27-484.8%	$0.33+109.9%	-$3.32+16.4%	-$3.97-260.9%	-$1.10+16.0%	-$1.31-13200.0%	$0.01-98.9%	$0.89+134.2%	$0.38+188.4%	-$0.43-186.0%	$0.50-29.6%	$0.71-16.5%	$0.85+73.5%	$0.49+226.7%	$0.15

Metric	Q1'27	Q4'26	Q3'26	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25
Revenue	$34.2M+47.3%	$23.2M	N/A	$31.1M-14.6%	$36.4M+3.7%	$35.2M+8.0%	$32.6M+31.8%	$24.7M
Cost of Revenue	$22.1M+17.9%	$18.7M	N/A	$23.3M+3.8%	$22.5M-11.2%	$25.3M+17.8%	$21.5M+11.2%	$19.3M
Gross Profit	$12.1M+170.6%	$4.5M	N/A	$7.8M-44.3%	$14.0M+42.0%	$9.8M-11.2%	$11.1M+105.8%	$5.4M
R&D Expenses	$1.5M+26.3%	$1.2M	N/A	$2.0M-6.7%	$2.1M+2.8%	$2.0M+6.3%	$1.9M-12.0%	$2.2M
SG&A Expenses	$8.0M+0.7%	$7.9M	N/A	$8.9M-0.9%	$9.0M-10.0%	$10.0M-10.3%	$11.1M-24.8%	$14.8M
Operating Income	$2.6M+154.9%	-$4.7M	N/A	-$3.1M-157.6%	$5.3M+159.0%	-$9.0M-360.9%	-$2.0M+83.1%	-$11.6M
Interest Expense	$7.8M+5.5%	$7.3M	N/A	$6.4M+11.5%	$5.7M+2.5%	$5.6M	N/A	$5.4M
Income Tax	$23K-46.5%	$43K	N/A	$333K+909.1%	$33K+512.5%	-$8K-118.6%	$43K+272.0%	-$25K
Net Income	-$6.2M+58.9%	-$15.0M	N/A	-$10.0M-771.1%	-$1.1M+92.2%	-$14.8M-124.8%	-$6.6M+59.5%	-$16.2M
EPS (Diluted)	-$0.19+55.8%	-$0.43	N/A	-$0.29	-$0.06	-$0.42-68.0%	-$0.25+52.8%	-$0.53

LFCR Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

LFCR quarterly balance sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Total Assets	$239.3M-5.8%	$254.0M+0.2%	$253.5M-7.7%	$274.7M-45.3%	$501.9M+71.0%	$293.5M-43.5%	$519.1M+28.3%	$404.7M+12.9%	$358.6M+4.7%	$342.7M-1.1%	$346.5M+10.5%	$313.6M+7.8%	$290.9M+4.8%	$277.7M+34.6%	$206.3M
Current Assets	$85.7M+5.7%	$81.0M-13.7%	$93.9M-19.5%	$116.7M-19.7%	$145.3M-7.5%	$157.1M+18.1%	$133.0M+37.1%	$97.1M+19.4%	$81.3M-5.8%	$86.3M-7.4%	$93.2M+2.5%	$90.9M+6.2%	$85.7M+5.5%	$81.2M-5.2%	$85.6M
Cash & Equivalents	$8.3M-2.3%	$8.5M-55.7%	$19.1M+1826.4%	$991K+29.9%	$763K+111.9%	$360K-66.7%	$1.1M-62.7%	$2.9M-51.7%	$6.0M-39.8%	$10.0M-29.4%	$14.1M-0.8%	$14.2M+3.8%	$13.7M-38.1%	$22.2M+172.6%	$8.1M
Inventory	$32.3M-19.2%	$40.0M-2.1%	$40.8M+13.4%	$36.0M+6.1%	$33.9M-48.8%	$66.3M+22.5%	$54.1M+70.1%	$31.8M+34.7%	$23.6M-7.5%	$25.5M+2.0%	$25.0M+1.2%	$24.7M+2.6%	$24.1M+9.5%	$22.0M+9.2%	$20.2M
Accounts Receivable	N/A	$31.2M+7.3%	$29.0M-24.2%	$38.3M+21.3%	$31.6M-58.5%	$76.2M+9.5%	$69.6M+29.1%	$53.9M+17.4%	$45.9M-1.1%	$46.4M-0.2%	$46.5M+4.6%	$44.4M+21.9%	$36.4M+14.0%	$32.0M+47.6%	$21.7M
Goodwill	$13.9M0.0%	$13.9M0.0%	$13.9M0.0%	$13.9M0.0%	$13.9M-59.1%	$33.9M-55.8%	$76.7M+40.8%	$54.5M0.0%	$54.5M+9.9%	$49.6M0.0%	$49.6M0.0%	$49.6M0.0%	$49.6M0.0%	$49.6M+36.1%	$36.5M
Total Liabilities	$240.2M+20.1%	$200.1M-8.4%	$218.5M+16.9%	$186.9M-37.7%	$299.9M+371.1%	$63.7M-74.4%	$248.9M+63.6%	$152.1M+16.6%	$130.5M+0.1%	$130.3M+3.1%	$126.4M+16.1%	$108.9M-1.5%	$110.5M-12.4%	$126.1M+83.9%	$68.6M
Current Liabilities	$30.2M-22.4%	$38.9M-1.1%	$39.3M-77.8%	$176.6M+73.4%	$101.9M	N/A	$137.1M+55.1%	$88.4M+71.8%	$51.5M-8.7%	$56.3M+0.3%	$56.2M+16.1%	$48.4M-4.7%	$50.8M-23.9%	$66.7M+117.2%	$30.7M
Long-Term Debt	$130.4M+29.4%	$100.8M+19.7%	$84.3M	N/A	$164.9M	N/A	$87.2M+133.4%	$37.4M-11.7%	$42.3M-8.0%	$46.0M+34.6%	$34.2M+20.7%	$28.3M-17.6%	$34.4M-14.7%	$40.3M+160.0%	$15.5M
Total Equity	-$861K-107.6%	$11.3M+367.5%	-$4.2M-104.8%	$87.8M-56.5%	$201.9M-12.1%	$229.8M-14.9%	$270.1M+7.0%	$252.6M+11.5%	$226.6M+7.5%	$210.7M-3.5%	$218.4M+7.6%	$203.1M+13.6%	$178.7M+19.3%	$149.7M+10.1%	$136.1M
Retained Earnings	-$205.2M-23.3%	-$166.5M+6.7%	-$178.5M-126.1%	-$79.0M-309.2%	$37.7M-47.0%	$71.2M-35.1%	$109.7M+0.4%	$109.3M+29.4%	$84.5M+15.0%	$73.5M-13.7%	$85.1M+18.9%	$71.6M+36.5%	$52.4M+75.7%	$29.8M+74.1%	$17.1M

Metric	Q1'27	Q4'26	Q3'26	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25
Total Assets	$229.5M+1.8%	$225.5M-2.9%	$232.2M-1.3%	$235.2M-1.7%	$239.3M+0.7%	$237.7M-6.9%	$255.4M+3.5%	$246.8M
Current Assets	$83.7M+7.8%	$77.6M-5.7%	$82.3M-1.9%	$83.9M-2.0%	$85.7M+1.7%	$84.2M+2.9%	$81.9M+10.3%	$74.2M
Cash & Equivalents	$17.2M-17.1%	$20.8M+19.0%	$17.5M-7.4%	$18.9M+128.1%	$8.3M+52.6%	$5.4M-42.7%	$9.5M+71.3%	$5.5M
Inventory	$25.5M-9.5%	$28.2M-3.2%	$29.1M-14.0%	$33.8M+4.7%	$32.3M-6.7%	$34.6M-11.8%	$39.2M-5.8%	$41.6M
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	$30.3M+20.5%	$25.1M
Goodwill	$13.9M0.0%	$13.9M0.0%	$13.9M0.0%	$13.9M0.0%	$13.9M0.0%	$13.9M0.0%	$13.9M0.0%	$13.9M
Total Liabilities	$263.6M+3.8%	$253.9M+3.1%	$246.4M+0.3%	$245.7M+2.3%	$240.2M+26.2%	$190.3M-2.7%	$195.6M-5.6%	$207.3M
Current Liabilities	$21.6M+5.6%	$20.5M-13.0%	$23.6M-21.3%	$30.0M-0.7%	$30.2M-3.0%	$31.1M-11.8%	$35.3M-12.9%	$40.5M
Long-Term Debt	$155.1M+4.3%	$148.7M+4.6%	$142.2M+4.6%	$136.0M+4.2%	$130.4M+4.4%	$124.9M+13.0%	$110.5M+4.7%	$105.5M
Total Equity	-$34.1M-19.9%	-$28.4M-100.2%	-$14.2M-34.8%	-$10.5M-1123.8%	-$861K-138.8%	$2.2M-85.6%	$15.4M+492.2%	-$3.9M
Retained Earnings	-$244.3M-2.6%	-$238.2M-6.7%	-$223.2M-2.3%	-$218.1M-6.3%	-$205.2M-0.6%	-$204.1M-6.6%	-$191.5M-4.8%	-$182.8M

LFCR Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.

LFCR quarterly cash flow statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Operating Cash Flow	-$206K-180.2%	$257K+101.5%	-$17.4M+22.8%	-$22.6M-237.2%	$16.5M+196.7%	-$17.0M-206.4%	$16.0M-19.0%	$19.8M-33.7%	$29.8M+43.7%	$20.8M-22.0%	$26.6M+26.5%	$21.0M-0.9%	$21.2M-4.3%	$22.2M+53.3%	$14.5M
Capital Expenditures	$13.4M-27.1%	$18.4M	N/A	$26.2M+36.1%	$19.3M+57.7%	$12.2M-72.7%	$44.7M+33.2%	$33.6M+46.0%	$23.0M-42.1%	$39.7M+126.7%	$17.5M+17.6%	$14.9M+67.7%	$8.9M+65.3%	$5.4M-19.6%	$6.7M
Free Cash Flow	-$13.6M+24.9%	-$18.1M	N/A	-$48.8M-1647.9%	-$2.8M+90.5%	-$29.3M-1.9%	-$28.7M-107.9%	-$13.8M-302.1%	$6.8M+136.1%	-$18.9M-307.9%	$9.1M+47.9%	$6.2M-50.1%	$12.4M-26.5%	$16.8M+115.9%	$7.8M
Investing Cash Flow	-$6.4M+65.1%	-$18.4M-282.4%	-$4.8M-106.0%	$80.0M+749.6%	-$12.3M+48.5%	-$23.9M+75.3%	-$96.8M-172.0%	-$35.6M-40.0%	-$25.4M+37.1%	-$40.4M	N/A	N/A	-$10.4M+76.4%	-$44.1M-50.0%	-$29.4M
Financing Cash Flow	$6.4M-14.4%	$7.5M-81.1%	$39.7M+169.6%	-$57.0M-1567.8%	-$3.4M-108.5%	$40.0M-49.4%	$79.0M+494.5%	$13.3M+251.0%	-$8.8M-157.1%	$15.4M	N/A	N/A	-$19.3M-153.6%	$35.9M+854.3%	-$4.8M
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$5.0M+322.8%	$1.2M

Metric	Q1'27	Q4'26	Q3'26	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25
Operating Cash Flow	-$2.2M-146.6%	$4.7M	N/A	$1.8M-67.0%	$5.3M+346.0%	$1.2M+119.5%	-$6.1M-901.6%	-$613K
Capital Expenditures	$513K-54.1%	$1.1M	N/A	$1.7M-17.2%	$2.1M-61.6%	$5.5M+123.6%	$2.4M-28.7%	$3.4M
Free Cash Flow	-$2.7M-175.4%	$3.6M	N/A	$25K-99.2%	$3.3M+176.3%	-$4.3M+50.4%	-$8.6M-112.6%	-$4.0M
Investing Cash Flow	-$513K+54.1%	-$1.1M	N/A	-$1.7M+17.2%	-$2.1M-235.8%	$1.5M+163.3%	-$2.4M+28.7%	-$3.4M
Financing Cash Flow	-$852K-232.8%	-$256K	N/A	-$1.4M-245.3%	-$402K+94.1%	-$6.8M-154.2%	$12.5M+1045.0%	$1.1M

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

LFCR Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples.

LFCR quarterly financial ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11
Gross Margin	31.3%-1.4pp	32.6%+5.5pp	27.1%-8.0pp	35.1%-3.5pp	38.6%+14.0pp	24.6%+10.1pp	14.5%-0.4pp	14.9%-1.9pp	16.9%+2.9pp	14.0%+1.9pp	12.1%-1.0pp	13.1%-1.1pp	14.2%-2.2pp	16.4%-0.4pp	16.9%
Operating Margin	-13.4%-6.5pp	-6.9%+14.2pp	-21.1%-10.5pp	-10.6%-1.9pp	-8.8%+7.4pp	-16.2%-17.2pp	1.0%-1.6pp	2.6%-0.5pp	3.1%+7.4pp	-4.3%-7.8pp	3.4%-0.8pp	4.2%-1.4pp	5.6%+1.0pp	4.6%+1.7pp	2.9%
Net Margin	-30.0%-39.4pp	9.4%+105.8pp	-96.5%	-104.9%	-32.0%-8.1pp	-23.9%-23.9pp	0.1%-4.7pp	4.7%+2.5pp	2.3%+4.7pp	-2.4%-5.0pp	2.5%-1.5pp	4.0%-1.1pp	5.1%+1.1pp	4.0%+2.6pp	1.4%
Return on Equity	N/A	106.0%	N/A	-132.9%-116.9pp	-16.0%+0.6pp	-16.6%-16.8pp	0.1%-9.7pp	9.8%+5.2pp	4.7%+10.2pp	-5.5%-11.7pp	6.2%-3.2pp	9.4%-3.2pp	12.6%+4.2pp	8.5%+5.6pp	2.9%
Return on Assets	-16.2%-20.9pp	4.7%+44.0pp	-39.3%+3.2pp	-42.5%-36.1pp	-6.4%+6.6pp	-13.0%-13.1pp	0.1%-6.1pp	6.1%+3.2pp	2.9%+6.3pp	-3.4%-7.3pp	3.9%-2.2pp	6.1%-1.7pp	7.8%+3.2pp	4.6%+2.7pp	1.9%
Current Ratio	2.84+0.8x	2.08-0.3x	2.39+1.7x	0.66-0.8x	1.43	N/A	0.97-0.1x	1.10-0.5x	1.580.0x	1.53-0.1x	1.66-0.2x	1.88+0.2x	1.69+0.5x	1.22-1.6x	2.79
Debt-to-Equity	N/A	8.91	N/A	2.13+1.3x	0.82+0.5x	0.280.0x	0.32+0.2x	0.150.0x	0.190.0x	0.22+0.1x	0.160.0x	0.14-0.1x	0.19-0.1x	0.27+0.2x	0.11
FCF Margin	-10.6%+3.6pp	-14.1%	N/A	-43.9%-41.1pp	-2.8%+15.5pp	-18.3%-13.1pp	-5.1%-2.5pp	-2.6%-4.1pp	1.5%+5.4pp	-4.0%-5.7pp	1.7%+0.4pp	1.3%-1.5pp	2.8%-2.5pp	5.3%+2.5pp	2.8%

Metric	Q1'27	Q4'26	Q3'26	Q2'26	Q4'25	Q3'25	Q2'25	Q1'25
Gross Margin	35.3%+16.1pp	19.2%	N/A	25.0%-13.3pp	38.4%+10.4pp	28.0%-6.0pp	34.0%+12.2pp	21.8%
Operating Margin	7.5%+27.6pp	-20.1%	N/A	-9.9%-24.5pp	14.6%+40.3pp	-25.7%-19.7pp	-6.0%+40.9pp	-46.9%
Net Margin	-18.0%+46.6pp	-64.6%	N/A	-32.1%-29.0pp	-3.1%+38.9pp	-42.0%-21.8pp	-20.2%+45.5pp	-65.7%
Return on Equity	N/A	N/A	N/A	N/A	N/A	-665.0%-622.4pp	-42.5%	N/A
Return on Assets	-2.7%+4.0pp	-6.6%	N/A	-4.3%-3.8pp	-0.5%+5.7pp	-6.2%-3.6pp	-2.6%+4.0pp	-6.6%
Current Ratio	3.87+0.1x	3.79+0.3x	3.49+0.7x	2.800.0x	2.84+0.1x	2.71+0.4x	2.32+0.5x	1.83
Debt-to-Equity	N/A	N/A	N/A	N/A	N/A	56.25+49.1x	7.15	N/A
FCF Margin	-7.9%-23.4pp	15.4%	N/A	0.1%-8.8pp	8.9%+21.0pp	-12.1%+14.2pp	-26.4%-10.0pp	-16.3%

Note: Shareholder equity is negative (-$861K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Aurora Cannabis Inc ACB

$253.9M

Alpha Teknova TKNO

$392.5M

Organigram Global Inc OGI

$173.4M

China Sxt Pharmaceuticals Inc SXTC

$1.8M

Ironwood IRWD

$700.6M

Where Lifecore Biomedical Inc Ranks

Frequently Asked Questions

What is Lifecore Biomedical Inc's annual revenue?

Lifecore Biomedical Inc (LFCR) reported $128.9M in total revenue for fiscal year 2025. This represents a 0.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Lifecore Biomedical Inc's revenue growing?

Lifecore Biomedical Inc (LFCR) revenue grew by 0.5% year-over-year, from $128.3M to $128.9M in fiscal year 2025.

Is Lifecore Biomedical Inc profitable?

No, Lifecore Biomedical Inc (LFCR) reported a net income of -$38.7M in fiscal year 2025, with a net profit margin of -30.0%.

What is Lifecore Biomedical Inc's EBITDA?

Lifecore Biomedical Inc (LFCR) had EBITDA of -$9.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Lifecore Biomedical Inc have?

As of fiscal year 2025, Lifecore Biomedical Inc (LFCR) had $8.3M in cash and equivalents against $130.4M in long-term debt.

What is Lifecore Biomedical Inc's gross margin?

Lifecore Biomedical Inc (LFCR) had a gross margin of 31.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Lifecore Biomedical Inc's operating margin?

Lifecore Biomedical Inc (LFCR) had an operating margin of -13.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Lifecore Biomedical Inc's net profit margin?

Lifecore Biomedical Inc (LFCR) had a net profit margin of -30.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Lifecore Biomedical Inc's free cash flow?

Lifecore Biomedical Inc (LFCR) recorded an outflow of $13.6M in free cash flow during fiscal year 2025. This represents a 24.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Lifecore Biomedical Inc's operating cash flow?

Lifecore Biomedical Inc (LFCR) recorded an outflow of $206K in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Lifecore Biomedical Inc's total assets?

Lifecore Biomedical Inc (LFCR) had $239.3M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Lifecore Biomedical Inc's capital expenditures?

Lifecore Biomedical Inc (LFCR) invested $13.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Lifecore Biomedical Inc spend on research and development?

Lifecore Biomedical Inc (LFCR) invested $8.3M in research and development during fiscal year 2025.

How many shares does Lifecore Biomedical Inc have outstanding?

Lifecore Biomedical Inc (LFCR) had 37M shares outstanding as of fiscal year 2025.

What is Lifecore Biomedical Inc's current ratio?

Lifecore Biomedical Inc (LFCR) had a current ratio of 2.84 as of fiscal year 2025, which is generally considered healthy.

What is Lifecore Biomedical Inc's return on assets (ROA)?

Lifecore Biomedical Inc (LFCR) had a return on assets of -16.2% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

Why is Lifecore Biomedical Inc's debt-to-equity ratio negative or not reported?

Lifecore Biomedical Inc (LFCR) has negative shareholder equity of -$861K as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Lifecore Biomedical Inc's Altman Z-Score?

Lifecore Biomedical Inc (LFCR) has an Altman Z-Score of -0.19, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Lifecore Biomedical Inc's Piotroski F-Score?

Lifecore Biomedical Inc (LFCR) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Lifecore Biomedical Inc's earnings high quality?

Lifecore Biomedical Inc (LFCR) reported a net loss of $38.7M while operations used $206K of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Lifecore Biomedical Inc cover its interest payments?

Lifecore Biomedical Inc (LFCR) reported an operating loss of $17.2M against $22.2M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Lifecore Biomedical Inc?

Lifecore Biomedical Inc (LFCR) scores 52 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.